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Abstract 
Introduction: Milrinone is an inotrope widely used for treatment of cardiac failure. Because previous meta-analyses 
had methodological flaws, we decided to conduct a systematic review of the effect of milrinone in critically ill adult 
patients with cardiac dysfunction.
Methods: This systematic review was performed according to The Cochrane Handbook for Systematic Reviews of 
Interventions. Searches were conducted until November 2015. Patients with cardiac dysfunction were included. The 
primary outcome was serious adverse events (SAE) including mortality at maximum follow-up. The risk of bias was 
evaluated and trial sequential analyses were conducted. The quality of evidence was assessed by the Grading of Rec-
ommendations Assessment, Development and Evaluation criteria.
Results: A total of 31 randomised clinical trials fulfilled the inclusion criteria, of which 16 provided data for our analy-
ses. All trials were at high risk of bias, and none reported the primary composite outcome SAE. Fourteen trials with 
1611 randomised patients reported mortality data at maximum follow-up (RR 0.96; 95% confidence interval 0.76–
1.21). Milrinone did not significantly affect other patient-centred outcomes. All analyses displayed statistical and/or 
clinical heterogeneity of patients, interventions, comparators, outcomes, and/or settings and all featured missing data.
Discussion: The current evidence on the use of milrinone in critically ill adult patients with cardiac dysfunction 
suffers from considerable risks of both bias and random error and demonstrates no benefits. The use of milrinone 
for the treatment of critically ill patients with cardiac dysfunction can be neither recommended nor refuted. Future 
randomised clinical trials need to be sufficiently large and designed to have low risk of bias.
Keywords: Milrinone, Systematic review, Heart failure, Trial sequential analysis
Introduction
Milrinone (Corotrope®/Primacor®) is a type III phos-
phodiesterase inhibitor primarily used for inotropic sup-
port in the treatment of cardiac dysfunction. Although 
milrinone is implemented in several guidelines, its effi-
cacy and safety profile remain controversial [1, 2].
Three meta-analyses have evaluated milrinone in criti-
cally ill patients [3–5]. One meta-analysis included adult 
cardiac surgery patients and observed that milrinone was 
associated with a significant increase in mortality while 
an update of the review found no significant effects [4, 
5]. One other meta-analysis evaluated milrinone for the 
treatment of acute heart failure after acute myocardial 
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infarction and suggested that milrinone might be safe and 
effective in these patients [3]. Unfortunately, only four tri-
als with a limited number of 303 patients were included.
None of these meta-analyses met all key methodo-
logical criteria for being a systematic review [6]. None 
of them were based upon a previously published proto-
col [3–5]. They lacked or had insufficient assessment of 
the risk of bias, and bias risks were insufficiently incor-
porated in the analyses and conclusions. They also lacked 
sufficient evaluation of the risks of random errors [7–9]. 
Just one domain having unclear risk of bias or high risk of 
bias is potentially sufficient to bias the findings. Further-
more, none of the previous meta-analyses assessed the 
outcomes according to the patients’ perspective following 
the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) [10]. GRADE assesses the 
quality of evidence by evaluating risk of bias, heterogene-
ity, indirectness, imprecision and publication bias [10].
Our objective was to perform a systematic review with 
meta-analyses and trial sequential analysis (TSA) of ran-
domised clinical trials (RCTs) according to The Cochrane 
Handbook for Systematic Reviews of Interventions and 
The Cochrane Hepato-Biliary Group Module comparing 
the benefits and harms of milrinone in critically ill adult 
patients with cardiac dysfunction [6, 7].
Methods
This systematic review was conducted according to our 
published protocol following the recommendations of 
The Cochrane Handbook for Systematic Reviews of Inter-
ventions and The Cochrane Hepato-Biliary Group Mod-
ule and reported according to the PRISMA statement [6, 
7, 11]. The protocol for this systematic review was regis-
tered at PROSPERO (no. CRD42014009061) [12].
Eligibility criteria
We considered all randomised clinical trials for inclu-
sion, irrespective of language, blinding, publication sta-
tus or sample size for assessment of benefits and harms. 
Quasi-randomised studies and observational studies 
with more than 500 patients were not included regarding 
assessment of benefits, but were considered for inclusion 
regarding assessment of harms and were planned to be 
analysed separately from the randomised trials [6].
Only trials with adult patients having cardiac dysfunc-
tion were considered. Cardiac dysfunction was defined 
as left ventricular ejection fraction (LVEF) below 40  % 
and/or low cardiac output. Low cardiac output syndrome 
was defined as a pre-existing or developing state of car-
diac insufficiency with underlying left or right ventricu-
lar systolic dysfunction requiring inotrope support [13]. 
We accepted the definitions of the diagnoses according 
to the criteria used in each individual randomised trial. 
Milrinone was considered the experimental interven-
tion. There were no restrictions on dose, continuous or 
intermittent administration, or duration of treatment. 
However, trials with oral and/or inhaled milrinone were 
excluded as such routes of administration were judged 
inappropriate for critically ill patients.
All trials were included independent the type of control 
intervention, i.e., no intervention, placebo, dobutamine, 
levosimendan, or any other inotrope or vasopressor. 
While this may introduce heterogeneity, subgroup com-
parisons were preplanned according to inactive (placebo 
or no intervention) and potentially active control inter-
ventions (e.g., other inotropes or vasopressors).
All outcomes were graded according to the patients’ per-
spective following GRADE [9]. The primary outcome was 
serious adverse events (SAE). SAE is a composite outcome 
summarising all serious events necessitating an intervention, 
operation, prolonged hospital stay or mortality according 
to ICH-GCP definitions [14]. This outcome was chosen for 
balancing the potential benefits and harms. The secondary 
outcomes were all-cause mortality, myocardial infarction, 
arrhythmia (including supra- and ventricular tachycardia 
and ventricular fibrillation) and duration of mechanical ven-
tilation. Time-specific analyses of mortality were conducted 
according to availability of data (e.g. 30, 90 and/or 180 days). 
Length of stay (both intensive care unit and total hospital 
stay) is a potentially highly biased surrogate outcome for 
recovery and was therefore not considered.
Search strategy
We searched the Cochrane Central Register of Controlled 
Trials (CENTRAL) in The Cochrane Library, PubMed/
MEDLINE, EMBASE, Web of Science and CINAHL until 
November 2015 (see supplements). We searched the ref-
erences of the identified trials and systematic reviews to 
identify any further relevant trials, i.e. backward snow-
balling. We also searched the WHO’s trial platform and 
ClinicalTrials.gov for ongoing trials and contacted the 
FDA and EMA.
Study selection and data extraction
Two authors independently identified the trials for 
inclusion. Excluded studies were listed with reasons for 
exclusion. The following data was extracted: year of pub-
lication, country in which the trial was conducted, year 
of conduct of the trial, single-centre or multicentre trial, 
inclusion and exclusion criteria, all outcomes, details on 
interventions and characteristics of the trials, e.g. base-
line imbalance, early stopping and other than intention-
to-treat analysis. The authors of the individual trials were 
contacted in case of any unclear or missing information.
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Bias risk assessment
Two authors independently assessed the risks of bias of 
the trials following instructions in The Cochrane Hand-
book for Systematic Reviews of Interventions [6]. The 
following risk of bias domains were extracted from each 
trial: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding 
of outcome assessors, incomplete outcome data, selec-
tive outcome reporting and other bias including bias due 
to vested interest and/or academic bias [15–20]. Trials 
were classified as low risk of bias if all the domains were 
assessed as low risk. Trials were considered to have high 
risk of bias if one or more of these bias risk domains were 
scored as unclear or high risk of bias.
Error matrix approach
Data on the outcomes of all trials were assessed for the 
risks of bias (measured by the level of evidence), the risks 
of random error (measured by standard error) and design 
errors (measured by GRADING the outcomes) [21]. The 
three-dimensional Manhattan error matrix was used to 
facilitate the overview of available evidence at a glance 
[21].
Statistical analysis
We performed the meta-analyses according to The 
Cochrane Handbook for Systematic Reviews of Interven-
tions [6] and The Cochrane Hepato-Biliary Group Mod-
ule [7] and used the software package Review Manager 
5.30 [22]. For TSA, the TSA program v.0.9beta (http://
www.ctu.dk/tsa) was used [23].
Results were presented as relative risks (RR) with 95 % 
confidence interval (CI) if there were two or more tri-
als for an outcome. For rare events (<5 % in the control 
group) we calculated odds ratios (OR) and for very rare 
events (<2  % in the control group) we calculated Peto’s 
OR with 95 % CI [24]. We also reported risk differences 
(RD) if conclusions were different from risk ratio. P val-
ues less than TSA-adjusted significance levels were con-
sidered statistically significant.
We calculated both a fixed-effect [25] and a random-
effects [26] model for meta-analysis and presented both 
models in case of discrepancy. Considering the antici-
pated clinical heterogeneity we emphasised the random-
effects model except if one or two trials dominated the 
available evidence [27]. Heterogeneity was explored by 
the Chi-squared test with significance set at a P value of 
0.10, and the quantity was measured by I2 [6, 28].
Analyses were performed on intention-to-treat [6]. 
In case of statistically significant RR, we calculated the 
number needed to treat (NNT) or number needed to 
harm (NNH) with 95 % CI.
Predefined subgroup analyses were conducted accord-
ing to (1) the bias risk of trials (low risk of bias compared 
to trials with unclear and high risk of bias; hypothesis: 
trials with unclear or high risk of bias are associated with 
more favourable beneficial effects); (2) the control inter-
vention (inactive compared to potentially active; hypoth-
esis: milrinone appears more favourable when compared 
to an inactive control intervention than potentially active 
control intervention); (3) clinical setting (patients having 
cardiac surgery compared to patients not having cardiac 
surgery; hypothesis: milrinone shows benefit in patients 
having cardiac surgery and not in other patients).
Funnel plots were used to explore small trial bias when 
data of more than ten randomised trials were available [6, 
29, 30].
Trial sequential analysis (TSA)
We conducted TSA to control the statistically significance 
levels when data are reanalysed repetitively or are too 
sparse to draw firm conclusions, and accordingly, appro-
priately widen the confidence intervals [8, 9, 31–33]. TSA 
depends on the quantification of the required information 
size (the meta-analysis sample size). We calculated the 
diversity (D2)-adjusted required information size (DARIS) 
for a random-effects meta-analysis [34]. Trial sequential 
monitoring boundaries cannot be calculated when less than 
5  % of the DARIS has been accrued. We conducted TSA 
with the intention to maintain an overall 5 % risk of a type 
I error and a power of 90 %. We used the unweighted con-
trol event proportion in the control group and we antici-
pated an intervention effect of a 10 % relative risk reduction 
(RRR). Sensitivity analyses were conducted using an RRR of 
20 % as well as the lower confidence limit of the RRR of the 
intervention effect suggested by the meta-analysis of the 
trials with low risk of bias [27]. We intended to provide the 
CI adjusted for sparse data and repetitive testing, which we 
describe as the TSA-adjusted CI.
GRADE approach
We used the GRADE system to assess the quality of 
the body of evidence associated with each of the major 
outcomes in our review using GRADE software (ims.
cochrane.org/revman/other-resources/gradepro) [10]. 
The quality measure of a body of evidence considers 
within-study risk of bias, indirectness, heterogeneity, 
imprecision and risk of publication bias.
Results
The search strategy identified 9336 hits (Fig.  1). Three 
additional publications were identified by backward 
snowballing: two could be included [35, 36] and one 
was irretrievable [37]. After removal of duplicates and 
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screening, 244 hits remained. Of the 244 hits, 213 were 
excluded after full text evaluation. The remaining 31 
publications were included in this systematic review. All 
authors of the 31 publications were contacted for miss-
ing data; only three authors responded [38–40], but no 
additional data was obtained. Of the 31 publications, 15 
evaluated only surrogate outcomes (such as haemody-
namic variables). Accordingly, only 16 randomised trials 
provided data for analyses [35, 36, 38, 40–52].
No ongoing trials, quasi-randomised studies or obser-
vational studies were identified.
Characteristics of the included trials
The characteristics of the 16 randomised trials that pro-
vided data for analyses are listed (Table  1). Two trials 
used a three-arm parallel group design; all others had a 
two-arm parallel group design. There were five multicen-
tre trials.
Fig. 1 PRISMA flow diagram. Asterisk not available at Dutch libraries or the universities linked through the University of Groningen. Double asterisk 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eight trials evaluated patients after cardiac surgery 
[38, 41, 43, 45–48, 51], four trials evaluated patients with 
chronic heart failure [40, 42, 44, 50], three trials evalu-
ated patients with acute heart failure after acute myocar-
dial infarction [35, 36, 49] and one trial evaluated patients 
with severe sepsis [52].
Milrinone was administered in different doses. Nine 
trials used a 50 µg/kg bolus and one trial a 30 µg/kg bolus. 
Continuous infusion rates ranged from 0.25 to 1.0 µg/kg/
min. Eight trials used an inactive comparator and eight 
trials used a potentially active comparator, including cat-
echolamines, dobutamine, levosimendan, nifedipine or 
nesirrtide. Many trials applied milrinone as an add-on 
intervention to standard care including other inotropes.
Bias risk assessment
Three trials (19  %) had low risk of bias regarding 
sequence generation, two trials (13  %) had low risk of 
bias regarding allocation concealment, five trials (31  %) 
had low risk of bias regarding blinding of participants, 
six trials (38 %) had low risk of bias regarding blinding of 
outcome assessors, five trials (31 %) had low risk of bias 
regarding incomplete outcome data, four trials (25  %) 
were without selective outcome reporting and two trials 
(13 %) were assessed as low risk of bias concerning indus-
try and/or academic bias (Fig.  2). Accordingly, all trials 
were assessed as high risk of bias.
Outcomes
The pooled intervention effect estimates with the 95 % CI 
of the outcomes are specified according to control inter-
vention and setting (Table 2 and supplements).
In the absence of trials that reported the primary com-
posite outcome SAE including mortality, we have cho-
sen to report all-cause mortality at maximum follow-up 
as the most important outcome. There were insufficient 
data for time-specific analyses of mortality. Meta-regres-
sion was not performed because of insufficient data.
Subgroup analyses according to risk of bias were not per-
formed as no trial was assessed as having low risk of bias.
All analyses were conducted with stratification by con-
trol intervention, unless stated otherwise.
Comparison 1: all critically ill patients with cardiac 
dysfunction
All‑cause mortality Fourteen trials with 1611 ran-
domised patients reported mortality. Pooled data showed 
that mortality at maximal follow-up was 11  % in both 
groups (RR 0.96; 95 % CI 0.76–1.21; I2 0 %; Fig. 3).
Fig. 2 Risk of bias assessment. Review of authors’ judgements about 
each risk of bias domain for each included study. Red high risk, green 
low risk, yellow unclear
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Subgroup analyses on type of control intervention and 
clinical setting showed differences in mortality event pro-
portions in the control groups (inactive control group 
0–70 %; potentially active control group 9–73 %; cardiac 
surgery setting control group 0–7 %; non-cardiac surgery 
setting control group 0–73  %), but tests of interaction 
showed no statistically significant differences between 
the groups (P = 0.59 and P = 0.83, respectively; Table 2 
and supplements). No comparison could be analysed with 
TSA using the prespecified type I error of 5 % and type II 
error of 10 % because less than 5 % of DARIS was accrued.
As a sensitivity analysis, we conducted TSA with an 
RRR of 20 % and power of 80 % which showed that 20 % 
of the data was accrued and thousands of additional 
randomised patients are needed before futility or the 
required information size will be reached (RR 0.96; TSA 
adjusted CI 0.60–1.53; see supplements).
Myocardial infarction Five trials with 1120 patients 
reported myocardial infarction (MI). MI at maximal 
follow-up occurred in 3 % in the inactive control group 
versus 15 % in the potentially active control group. Two 
small trials [41, 45] had a potentially active control group. 
There were no statistically significant differences in MI 
between milrinone and any control group (RR 0.73; 95 % 
CI 0.25–2.09; I2 61 %, P = 0.48; Table 2). No comparison 
could be analysed with TSA using the prespecified type I 
error of 5 % and type II error of 10 % because less than 5 % 
of DARIS was accrued.
Subgroup analyses based on clinical setting revealed 
discrepancy between fixed- and random-effects models 
driven by different weighting of one trial with 94 % rela-
tive risk reduction (random-effects model RR 0.53; 95 % 
CI 0.24–1.17, and fixed-effect model RR 0.45; 95  % CI 
0.25–0.81; I2 34 %; see supplements) [48].
Other outcomes Ventricular tachyarrhythmias [i.e. ven-
tricular tachycardia (VT)/ventricular fibrillation (VF)] 
were reported in seven randomised trials (1226 patients) 
with equal event rate percentages (7  %) in both groups 
(RR 0.96; 95 % CI 0.65–1.41; I2 0 %). No comparison could 
be analysed with TSA using the prespecified type I error 
of 5 % and type II error of 10 % because less than 5 % of 
DARIS was accrued.
Table 2 Conventional risk ratios with  95  % confidence intervals (CI) for  the evaluated outcome measures including  all 
patients stratified by intervention
All pooled estimates are reported using risk ratio and calculated using a random-effects model unless stated otherwise. TSA adjusted risk ratios with the predefined 
α = 0.05 (two sided), β = 0.10 (power 90 %) and an anticipated relative risk increase of 10 % could not be calculated in any outcome with <5 % of the DARIS accrued
DARIS diversity adjusted required information size, MI myocardial infarction, SVT supraventricular tachyarrhythmia, VT/VF ventricular tachyarrhythmia, MV mechanical 
ventilation
a MV duration is reported in mean difference with 95 % CI
Number of trials Number of patients Conventional meta-analysis
RR with 95 % CI Test of interaction
Mortality
 Inactive control 5 1267 0.99 (0.77–1.27)
 Potentially active control 9 344 0.76 (0.31–1.89)
 Any control 14 1611 0.96 (0.76–1.21) P = 0.59
MI
 Inactive control 3 1060 0.54 (0.11–2.69)
 Potentially active control 2 60 1.09 (0.36–3.29)
 Any control 5 1120 0.73 (0.25–2.09) P = 0.48
VT/VF
 Inactive control 4 1087 0.80 (0.40–1.61)
 Potentially active control 3 139 1.11 (0.58–2.15)
 Any control 7 1226 0.96 (0.65–1.41) P = 0.50
SVT
 Inactive control 2 988 1.43 (0.80–2.54)
 Potentially active control 2 150 0.60 (0.13–2.70)
 Any control 4 1138 0.89 (0.43–1.87) P = 0.29
MV durationa
 Inactive control 2 150 −2.85 (−5.00 to −0.69)
 Potentially active control 2 60 12.66 (−3.48 to 28.80)
 Any control 4 210 1.03 (−4.87 to 6.93) P = 0.06
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The pooled results and the subgroup analyses showed 
no associations between milrinone and ventricular tach-
yarrhythmia (see supplements).
Supraventricular tachyarrhythmia’s (SVT) were 
reported in four trials (1138 patients). There was a statis-
tically significant heterogeneity between the trials in both 
subgroup analyses (both I2 55 %; P = 0.08). SVT varied 
from 5 to 18 % in the different subgroups (inactive versus 
potentially active and cardiac surgery versus non-cardiac 
surgery). Analyses of the pooled data (RR 0.89; 95 % CI 
0.43–1.87) and the subgroups showed no significant 
associations (see supplements). No comparison could be 
analysed with TSA using the prespecified type I error of 
5 % and type II error of 10 % since less than 5 % of DARIS 
was accrued.
Mechanical ventilation duration was reported in four 
trials (210 patients) in a cardiac surgery setting; duration 
ranged from 11 to 34 h in the control group and 10–65 h 
in the milrinone group. There was statistically significant 
heterogeneity (I2 80 %; P = 0.002). No significant differ-
ences were found. Test of interaction was not significant 
(P = 0.06).
Comparison 2: patients with cardiac dysfunction 
after cardiac surgery
All‑cause mortality Six trials with 279 randomised 
patients reported mortality data. Mortality at maximal 
follow-up was 4 % in both groups (RR 1.04; 95 % CI 0.30–
3.63; I2 0 %). No comparison could be analysed with TSA 
using the prespecified type I and type II error because less 
than 5 % of DARIS was accrued.
Two trials used an inactive comparator and four trials 
used a potentially active comparator. No significant asso-
ciations between milrinone and mortality were found 
(see supplements).
Myocardial infarction MI was reported in four trials 
including 210 patients. There was significant statistical het-
erogeneity between the trials (I2 58 %; P = 0.09). There was 
discrepancy between the fixed- and the random-effects mod-
els driven by different weighting of one trial [48] (fixed-effect 
model RR 0.42; 95 % CI 0.21–0.86; random-effects model RR 
0.47; 95 % CI 0.13–1.72; see supplements). No comparison 
could be analysed with TSA using the prespecified type I and 
type II error because less than 5 % of DARIS was accrued.
Fig. 3 Forest plot of all-cause mortality in trials stratified by intervention. Size of squares for risk ratio (RR) reflects the weight of the trial in the 












































































































































































































































































































































































































































































































































































































































































































































































Other outcomes Five trials with 240 patients docu-
mented ventricular tachyarrhythmia and no significant 
associations were found (see supplements).
SVTs were reported in three trials with 230 ran-
domised patients and no significant associations were 
found between milrinone and SVTs (see supplements).
Comparison 3: patients with cardiac dysfunction not having 
cardiac surgery
All‑cause mortality Eight trials with 1332 randomised 
patients reported mortality. Mortality at maximal follow-
up was 11  % in the milrinone group versus 12  % in the 
control group (RR 0.91; 95  % CI 0.64–1.28; I2 0  %). No 
comparison could be analysed with TSA using the pre-
specified type I error of 5  % and type II error of 10  % 
because less than 5 % of DARIS was accrued.
Three trials used an inactive control and five trials used 
a potentially active control. Subgroup analyses on type 
of control intervention showed no significant difference 
(test of interaction P  =  0.34). No significant associa-
tions between milrinone and mortality were found (see 
supplements).
Other outcomes Ventricular tachyarrhythmia’s (VT/VF) 
were reported in two trials (986 patients). No significant 
associations between milrinone and VT/VF were found 
(RR 1.19 95 % CI 0.68–2.06).
There was insufficient data on other secondary 
outcomes.
Error matrix approach
The Manhattan error matrix plots of milrinone showed 
that there is a similar amount of evidence regarding 
the benefits and harms of milrinone. All trials had high 
risks of systematic errors (bias) and the large major-
ity of the trials also had high risks of random errors (see 
supplements).
Small trial bias
Funnel plots showed no clear arguments for small trial 
bias including publication bias (see supplements).
GRADE approach
The quality of the evidence was assessed as very low for 
all outcomes based on risk of bias limitations, indirect-
ness, inconsistency, imprecision and other considera-
tions. Table 3 shows the GRADEpro summary of findings 
table with stratification by control intervention.
Discussion
Our systematic review evaluating the effects of milrinone 
for critically ill adult patients with cardiac dysfunction 











































































































































































































































































































































































































































































































































































































































































































































Thirty-one randomised clinical trials fulfilled our inclu-
sion criteria. All included trials had high risk of bias, most 
as a result of not reporting bias protection, and nearly 
all trials had large risks of random errors. Fifteen trials 
only reported surrogate outcomes. No trial reported the 
primary outcome, SAE (including mortality). All-cause 
mortality was reported in 14 trials with 1611 patients. 
No significant effect on any patient-centred outcome was 
found.
A general issue is that systematic reviews depend on 
the strengths of the included randomised trials. Tri-
als with unclear or high risks of bias are associated with 
overestimation of benefits and underestimation of harms 
[15, 16, 18, 19]. The unknown true intervention effect 
may be beneficial, neutral or harmful. Previous meta-
analyses on milrinone differ in design from our system-
atic review and they come to different conclusions [3–5]. 
One study focussed only on patients with myocardial 
infarction [3] and two only on cardiac surgery patients, 
in which the latter was an update [4, 5]. The meta-anal-
ysis on patients with myocardial infarction observed no 
significant effect on mortality, but stated that milrinone 
increased left ventricular ejection fraction and cardiac 
output [3]. The first meta-analysis evaluating patients 
having cardiac surgery suggested an increase in mortal-
ity using milrinone, which disappeared in the updated 
meta-analysis [4, 5]. Our prepublished protocol, a sensi-
tive search strategy and thorough evaluations of the risks 
of systematic errors and random errors may explain dif-
ferences with these previous publications [3–5]. First, 
previous meta-analyses ignored exploring associations of 
bias risk with intervention effect estimates. Final conclu-
sions ought to be derived from trials with low risk of bias, 
of which there were none [6]. Second, despite including 
more patients (n = 1611) as compared to previous meta-
analyses (n = 303 [3], n = 518 [4], n = 1037 [5]) the num-
ber of included patients is still far too small to draw any 
firm conclusions. We think that any significance needs 
the perspective of sample size considerations, in individ-
ual trials and also in meta-analyses [27, 31, 53–55]. Third, 
previous meta-analyses combined patients with normal 
cardiac functions [4, 5] and children [5] with patients 
with cardiac dysfunction into one pooled estimate. We 
included trials that randomised adult patients who had 
cardiac dysfunction. It is unlikely that patients benefit 
from milrinone when their cardiac function is unaffected, 
i.e. when the pathophysiological basis for cardiac stimu-
lation is lacking.
Co-interventions with medications with an efficacy 
profile similar to milrinone might also have obscured 
results. Trials that evaluated milrinone versus placebo 
could also be considered add-on trials since co-inter-
ventions were allowed. The largest trial that evaluated 
milrinone versus placebo allowed at least co-interven-
tions with dobutamine in their randomised patients; 
other inotropes were not reported [44]. The results of this 
trial suggest that milrinone may be harmful in patients 
with heart failure (LVEF <40 %) compared with standard 
treatment (ACE inhibitor and diuretics). Furthermore, 
the sickest patients were excluded in this trial [44]. For 
daily practice it is of utmost interest to know which vaso-
pressor, inotrope, vasodilator or any combination is indi-
cated for which patient and at what target [56, 57]. We 
found that for milrinone and levosimendan for critically 
ill adult patients with cardiac dysfunction evidence from 
trials with low risk of bias and low risk of random error 
is lacking to support its use [58]. Other interventions are 
currently being evaluated in systematic reviews which 
might feed future evidence-based guidance for clinicians 
or substantiate new trials.
Limitations
During the process of the systematic review we were non-
adherent to our prepublished protocol for several reasons. 
We rephrased the title and terminology for an improved 
description of the cardiac state of the patients at inter-
est (i.e. cardiac dysfunction instead of cardiac support 
or myocardial dysfunction). We divided subgroup com-
parisons into inactive versus (potentially) active control 
interventions. Since no data was found on the predefined 
subgroup comparison milrinone versus vasopressors 
we were unable to report this comparison. There were 
also no data on the composite outcome SAE (mortality 
included) and, therefore, all-cause mortality became the 
most important outcome. The outcome hypotension was 
regarded as a surrogate outcome and therefore omitted.
We frequently found significant statistical heterogene-
ity, but even when absent, there was still considerable 
clinical heterogeneity in patients, interventions, com-
parators, outcomes or settings. Pooling the data was 
frequently considered disputable, even in the absence of 
statistically significant tests of interactions. One exam-
ple is the pooled intervention effect estimate of mortality 
(comparison 1), which has low statistical heterogeneity 
(I2 0  %; P =  0.50) and no subgroup differences, but the 
clinical heterogeneity is obvious, also reflected by con-
trol event rates for all-cause mortality varying from 3.6 to 
12.0 %. The large variety in types of control interventions 
further increases clinical heterogeneity.
Milrinone dose and duration varied among the 
included trials. Also, there were differences in definitions 
of outcomes. Further, 15 trials evaluated surrogate out-
comes, such as haemodynamic and biochemical param-
eters. Finally, most trials had short follow-up; only one 
trial evaluated 1-year follow-up [51], so that mortality 
analyses reflect rather short follow-up.
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Conclusions
The quantity and quality of evidence for benefit or harm 
of milrinone in critically ill adult patients with cardiac 
dysfunction are very low because of high risks of system-
atic and random errors. Future randomised clinical trials 
need to be large and well designed by following SPIRIT 
guidelines and reported according to CONSORT guide-
lines. The widespread use of milrinone in critical care 
cannot be advocated or refuted on the basis of the cur-
rent evidence.
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